MedTrace Logo

A Phase II/III Study of IBB0979 in Combination With Topotecan Versus Topotecan in Relapsed Small Cell Lung Cancer

NCT07076095 · Status: NOT_YET_RECRUITING · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 200

Last updated 2025-07-21

No results posted yet for this study

Summary

This study was designed to compare the efficacy and safety of IBB0979 in combination with topotecan versus topotecan in subjects with relapsed small cell lung cancer (SCLC).

Conditions

Interventions

DRUG

IBB0979

bifunctional antibody-cytokine fusion protein that targets B7-H3 and IL-10 receptor

DRUG

topotecan hydrochloride for injection

Topotecan hydrochloride will be administered intravenously per prescribing information.

Sponsors & Collaborators

  • The Affiliated Cancer Hospital of Zhengzhou University & Henan Cancer Hospital

    collaborator UNKNOWN

  • SUNHO（China）BioPharmaceutical CO., Ltd.

    lead INDUSTRY

Principal Investigators

  • ming qi wang · The Affiliated Cancer Hospital of Zhengzhou University & Henan Cancer Hospital

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2025-08-01
Primary Completion
2028-08-01
Completion
2031-08-01
FDA Drug
Yes

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07076095 on ClinicalTrials.gov